Title
Culture conversion at 6 months in patients receiving delamanid-containing regimens for the treatment of multidrug-resistant tuberculosis
Date Issued
01 July 2020
Access level
metadata only access
Resource Type
journal article
Author(s)
Seung K.J.
Khan P.
Franke M.F.
Ahmed S.
Aiylchiev S.
Alam M.
Putri F.A.
Bastard M.
Docteur W.
Gottlieb G.
Hewison C.
Islam S.
Khachatryan N.
Kotrikadze T.
Khan U.
Kumsa A.
Tassew Y.M.
Melikyan N.
Naing Y.Y.
Oyewusi L.
Rich M.
Wanjala S.
Yedilbayev A.
Huerga H.
Mitnick C.D.
Publisher(s)
Oxford University Press
Abstract
Delamanid should be effective against highly resistant strains of Mycobacterium tuberculosis, but uptake has been slow globally. In the endTB (expand new drug markets for TB) Observational Study, which enrolled a large, heterogeneous cohorts of patients receiving delamanid as part of a multidrug regimen, 80% of participants experienced sputum culture conversion within 6 months.
Start page
415
End page
418
Volume
71
Issue
2
Language
English
OCDE Knowledge area
Enfermedades infecciosas
Sistema respiratorio
Subjects
Scopus EID
2-s2.0-85088200692
PubMed ID
Source
Clinical Infectious Diseases
ISSN of the container
10584838
Sources of information:
Directorio de Producción CientÃfica
Scopus